News archive
Showing 784 results
June 2026
-
Media Release
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
Phase III ALIGN study results showed reduced rate of kidney function decline by ~34% with Vanrafia vs placebo, based on supportive eGFR slope analysis1 Vanrafia reduced protein in urine by 38.3%… -
Media Release
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients
Clinically meaningful, statistically significant efficacy achieved in primary and all secondary endpoints, including reduced steroid use; safety consistent with established Cosentyx profile1,2… -
Story Education and Awareness
New Survey Reveals 4 Things Patients with HS Really Need
The hidradenitis suppurativa (HS) Community Mapping Project surveyed patients to create a roadmap for change. Here's what they shared.
-
Story Medicines
Carter’s Story: My Mom's Journey with Cancer Inspired Me. Now I Help Make Medicines for Patients
For Carter Jaynes, helping to produce doses of RLT is deeply personal. See how a move to our new RLT facility in Carlsbad can help him reach even more patients.
-
Media Release
Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML
Growing improvement in major molecular response (MMR) rates demonstrated with Scemblix vs. all standard-of-care TKIs including imatinib and second generation (2G) TKIs1 Clinically relevant 15.2%… -
Media Release
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
New Cosentyx® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica, to be highlighted in oral session New ianalumab interim results from Sjögren’s Phase…
May 2026
-
Media Release
Pluvicto® demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer
Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with Pluvicto plus standard of care (ARPI + ADT) in PSMAddition Consistent… -
Story Education and Awareness
The Novartis Next Generation Cancer Care Survey: A New Conversation about Care
In a nationwide survey, more than 2,000 patients, caregivers, and clinicians told us what cancer care gets right, and where we can collaborate to improve.
-
Media Release
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented 124-week Phase I/II zigakibart data evaluating treatment efficacy and safety in IgAN will be… -
Media Release
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
Pluvicto® PSMAddition oral presentation to highlight efficacy outcomes by disease volume and de novo/recurrent metastatic hormone-sensitive prostate cancer Kisqali® NATALEE oral presentation to… -
Story Access to Healthcare
Care Begins in Our Communities: 4 Things to Know About How We’re Investing in America’s Health
A year ago, we committed to investing $23 billion in America’s health over the next five years. Here’s a look at the impact we’ve made so far—plus a new initiative we’re launching in five cities to drive awareness and earlier detection of breast and prostate cancer.
-
Media Release
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto™ in metastatic hormone-sensitive prostate cancer
More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC alone in PSMAddition Deep PSA reduction higher in patients receiving Pluvicto…